Virtual Poster Session in NETs From Philadelphia - prIME Oncology
Virtual Poster
Virtual Poster

Virtual Poster Session in NETs From Philadelphia

Practical Application of Key Data Presented During the 2017 Neuroendocrine Tumors Annual Symposium in Philadelphia

Not a member of My prIME? Join now for instant access.

View abstract presentations and downloadable slides covering the most up-to-date clinical trial data in neuroendocrine tumors from NANETS 10th Annual Multidisciplinary NET Disease Symposium.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Oct 27, 2017

Expiration Date

Oct 27, 2018

Matthew H. Kulke, MD

Abstract #C-21: Change in patient-reported symptom control in patients with neuroendocrine tumors treated with lanreotide depot

Featured Expert: Matthew H. Kulke, MD

Matthew H. Kulke, MD

Abstract #C-5: Time to sustained improvement in bowel movement frequency with telotristat ethyl: Analysis of the phase 3 TELESTAR Study

Featured Expert: Matthew H. Kulke, MD

Jennifer Chan, MD, MPH

Abstract #C-4: Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors

Featured Expert: Jennifer Chan, MD, MPH

Andrew E. Hendifar, MD

Abstract #B-22: Molecular classification of neuroendocrine tumors: Clinical experience with the 92-gene assay in 24,000 cases     

Featured Expert: Andrew E. Hendifar, MD

Jonathan Strosberg, MD

Abstract #C-33: QOL improvements in NETTER-1 phase III trial in patients with progressive midgut neuroendocrine tumors

Featured Expert: Jonathan Strosberg, MD

This educational activity is supported by Ipsen.

Enduring Materials From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.


This activity is provided by prIME Oncology.

Disclosure Information


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.